The K-Beauty industry continues its rapid expansion into global markets, making the role of clinical institutions increasingly crucial.

Specifically, human efficacy testing institutions that scientifically validate product efficacy and safety have become foundational infrastructures for global expansion.

The Korean Dermatologic Research Institute (KDRI), established in 2012, has significantly contributed to the growth of the domestic cosmetics sector through precise clinical evaluations based on dermatological science.

Following its merger with GFC Life Sciences Co., Ltd. in 2019, the institute enhanced its competitive edge by establishing an integrated research and development system that spans from material development to clinical validation.

Currently, KDRI serves as a comprehensive testing and evaluation organization, offering a myriad of services including human efficacy testing, in vitro efficacy evaluations, health functional food assessments, and global certification and regulatory services.

Its 'total service' system provides tailored solutions for clients, covering everything from study design and results reporting to regulatory approvals and marketing utilization.

By incorporating specialists across various fields including dermatology, ophthalmology, and dentistry, alongside a dedicated research team in the bio and cosmetics sectors, KDRI ensures the collection of highly reliable data.

The institution also operates its own Institutional Review Board (IRB) to uphold ethical and safety standards in all tests conducted.

KDRI is a pioneer in developing differentiated testing methodologies, being the first in South Korea to create evaluation methods for blue light blocking and skin microbiome analysis, securing its leading position in the functional cosmetics evaluation sector.

With a steadfast commitment to providing 'accurate and trustworthy data', KDRI is positioning itself as a premier global evaluation organization.

### Accelerating Market Penetration

KDRI has identified global market expansion as a core strategy, bolstering its competitive posture through enhanced international networks and the advancement of clinical technologies.

Recently, partnerships have been established across North America, Japan, Thailand, Taiwan, and Italy, leading to a sustained increase in human efficacy test orders from international clients.

To promote its global market reach and showcase its research capabilities, KDRI is set to participate actively in international exhibitions, including the Asia Healthcare & Medical Cosmetology Expo in Taiwan in July and in-cosmetics Asia 2026 in Bangkok in November.

Targeting advanced markets with stringent cosmetic regulations and high demand for functional products, it is intensifying efforts to secure references that elevate its global credibility.

Moreover, to meet the diverse needs of global clients, KDRI has strengthened its operational capacities by acquiring a multi-ethnic panel, creating a testing environment capable of providing diverse skin type and ethnic data that are critical for clients aiming to enter overseas markets.

Building a virtuous cycle of material development, clinical verification, and commercialization through collaboration with GFC Life Sciences is also part of KDRI's corporate strategy as it transitions toward high-value clinical services.

Future plans include leveraging a global clinical platform, expanding participation in international exhibitions, and ramping up digital marketing initiatives to continuously amplify international sales and solidify its standing as a global clinical institution.

### Strengthening Regulatory Response Capabilities

As part of its strategy for global expansion, KDRI is proactively enhancing its regulatory compliance capabilities to navigate the complex regulatory environments of various countries.

Beginning in 2023, it has started to provide services for the National Medical Products Administration (NMPA) hygiene licensing in China, which includes local testing and usability evaluations.

Furthermore, starting in 2026, KDRI plans to roll out a comprehensive service for the Cosmetic Product Notification Portal (CPNP) registration in Europe, encompassing everything from product information file preparation to registration and post-management.

To establish a transparent system of raw material verification, KDRI has also implemented a DNA-based certification system that validates the origin and reliability of its ingredients.

In line with the strengthening of domestic safety evaluation and reporting systems, plans are underway to launch services for generating safety reports that assist companies in effectively addressing regulatory changes.

### Continuous Development of Differentiated Testing Methods

KDRI is committed to continuous research and development to create unique testing methodologies, having accumulated numerous patents and research achievements.

Notably, it has recently developed new evaluation methods for surfactant residue assessment in cleansers and analysis of niacinamide in the stratum corneum and fabric stress tests, thereby expanding its functional and safety evaluation sphere.

Its patented technology focused on surfactant residue assessment has notably enhanced KDRI’s competitive edge in cleanser evaluations.

Furthermore, the institute holds various patents for evaluations of blue light and infrared protection, while also leading next-generation testing technologies such as microbiome analysis.

Through collaborations with institutions like Seoul National University Hospital, KDRI is boosting the reliability of its clinical tests.

Plans for future growth include deepening collaborations with academic institutions and hospitals to continuously enhance the reliability of clinical data and research standards.

### Advanced Testing Infrastructure Leveraging a systematic organizational framework and robust research infrastructure, KDRI conducts thousands of clinical trials annually.

It operates several specialized laboratories focused on functional evaluations, UV testing, in vitro studies, and has established a high-level testing environment adapted to the market's evolving needs.

Amid the saturation and fierce competition of the cosmetics clinical market, characterized as a 'red ocean', maintaining a competitive edge through high-value testing and differentiated technologies is increasingly vital.

KDRI has targeted its strategies toward expanding high-functionality clinical trials, enhancing its global customer base, and introducing innovative evaluation methods and equipment.

### Leveraging Three Distinct Competitive Strengths for Growth KDRI has secured a unique position in the market through three distinct competitive advantages:

1. **Expertise in Functional Efficacy Testing**: By drawing on extensive experience and patent-based testing methods in areas such as whitening, anti-wrinkle, UV protection, and skin barrier evaluation, KDRI offers highly reliable data and stands out in regulatory responses related to functional cosmetics.

2. **Total Clinical Services and Global Response Capabilities**: An established one-stop service system encompassing everything from material development to clinical evaluations, regulatory compliance, and marketing utilization enables KDRI to effectively meet international client needs through a multi-ethnic panel and an extensive global network.

3. **Systematic Management and Human Resource Competitiveness**: The institute has ensured testing reliability through an IRB-based ethical system, a quality management framework focused on quality assurance, and organizational operations centered around expert researchers.

Continuous workforce expansion and specialized training further bolster its research capabilities.

In the coming years, the Korean Dermatologic Research Institute aims to solidify its role as a pivotal institution driving the competitiveness of the K-Beauty industry through its differentiated clinical evaluation technologies and global networks.